1875 Stock Overview
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 1875 from our risk checks.
TOT BIOPHARM International Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.58 |
| 52 Week High | HK$3.40 |
| 52 Week Low | HK$0.80 |
| Beta | 0.19 |
| 1 Month Change | 0% |
| 3 Month Change | -1.86% |
| 1 Year Change | -24.76% |
| 3 Year Change | -64.89% |
| 5 Year Change | n/a |
| Change since IPO | -74.76% |
Recent News & Updates
Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?
Mar 18
There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues
Dec 28Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?
Nov 23Recent updates
Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?
Mar 18There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues
Dec 28Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?
Nov 23We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt
May 18Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Jul 27An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued
Mar 26Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Feb 03Shareholder Returns
| 1875 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 3.9% | 5.7% | 3.6% |
| 1Y | -24.8% | -40.7% | -10.1% |
Price Volatility
| 1875 volatility | |
|---|---|
| 1875 Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.7% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 552 | Jun Liu | www.totbiopharm.com |
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. The company develops TAB008 for the treatment of non-squamous non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, fallopian tube cancer, or primary peritoneal cancer, and hepatocellular carcinoma. It also offers TOZ309 for the treatment of glioblastoma multiforme or anaplastic astrocytoma.
TOT BIOPHARM International Company Limited Fundamentals Summary
| 1875 fundamental statistics | |
|---|---|
| Market cap | HK$1.22b |
| Earnings (TTM) | -HK$40.80m |
| Revenue (TTM) | HK$843.46m |
1.4x
P/S Ratio-29.9x
P/E RatioIs 1875 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1875 income statement (TTM) | |
|---|---|
| Revenue | CN¥780.63m |
| Cost of Revenue | CN¥206.64m |
| Gross Profit | CN¥573.99m |
| Other Expenses | CN¥611.74m |
| Earnings | -CN¥37.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 73.53% |
| Net Profit Margin | -4.84% |
| Debt/Equity Ratio | 50.1% |
How did 1875 perform over the long term?
See historical performance and comparison